Anti-vWF Nanobody: Phase II started

Ablynx began an open-label, European Phase II trial to compare IV ALX-0081 vs. ReoPro abciximab, a GPIIb/IIIa (CD41/CD61) inhibitor, from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) in about 3...